Skip to main content
. 2023 Mar 1;114(5):2098–2108. doi: 10.1111/cas.15746

FIGURE 1.

FIGURE 1

Extraction of DNA and RNA from bone marrow (BM) clot specimens from AML patients and mutation analysis. (A) Consort diagram and success rate of DNA and RNA yielded from BM clot samples. (B) Distribution of tumor mutation burden according to the WHO 2017 classification in relapsed refractory (R/R)‐AML and newly diagnosed unfit AML. HSCT, hematopoietic stem cell transplantation; MRC, myelodysplasia‐related changes; RGA, recurrent genetic abnormality; t‐AML, therapy‐related AML